Displaying all 2 publications

Abstract:
Sort:
  1. Implementation of data intelligence models coupled with ensemble machine learning for prediction of water quality index
    Abba SI, Pham QB, Saini G, Linh NTT, Ahmed AN, Mohajane M, et al.
    Environ Sci Pollut Res Int, 2020 Nov;27(33):41524-41539.
    PMID: 32686045 DOI: 10.1007/s11356-020-09689-x
    In recent decades, various conventional techniques have been formulated around the world to evaluate the overall water quality (WQ) at particular locations. In the present study, back propagation neural network (BPNN) and adaptive neuro-fuzzy inference system (ANFIS), support vector regression (SVR), and one multilinear regression (MLR) are considered for the prediction of water quality index (WQI) at three stations, namely Nizamuddin, Palla, and Udi (Chambal), across the Yamuna River, India. The nonlinear ensemble technique was proposed using the neural network ensemble (NNE) approach to improve the performance accuracy of the single models. The observed WQ parameters were provided by the Central Pollution Control Board (CPCB) including dissolved oxygen (DO), pH, biological oxygen demand (BOD), ammonia (NH3), temperature (T), and WQI. The performance of the models was evaluated by various statistical indices. The obtained results indicated the feasibility of the developed data intelligence models for predicting the WQI at the three stations with the superior modelling results of the NNE. The results also showed that the minimum values for root mean square (RMS) varied between 0.1213 and 0.4107, 0.003 and 0.0367, and 0.002 and 0.0272 for Nizamuddin, Palla, and Udi (Chambal), respectively. ANFIS-M3, BPNN-M4, and BPNN-M3 improved the performance with regard to an absolute error by 41%, 4%, and 3%, over other models for Nizamuddin, Palla, and Udi (Chambal) stations, respectively. The predictive comparison demonstrated that NNE proved to be effective and can therefore serve as a reliable prediction approach. The inferences of this paper would be of interest to policymakers in terms of WQ for establishing sustainable management strategies of water resources.
  2. Fulltext Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
    Neuhann JM, Stemler J, Carcas AJ, Frías-Iniesta J, Akova M, Bethe U, et al.
    Vaccine, 2023 Nov 22;41(48):7166-7175.
    PMID: 37919141 DOI: 10.1016/j.vaccine.2023.10.029
    BACKGROUND: Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially for people of advanced age, however, optimal dosing regimens are as yet lacking.

    METHODS: EU-COVAT-1-AGED Part A is a randomised controlled, adaptive, multicentre phase II trial evaluating safety and immunogenicity of a 3rd vaccination (1st booster) in individuals ≥75 years. Fifty-three participants were randomised to full-doses of either mRNA-1273 (Spikevax®, 100 µg) or BNT162b2 (Comirnaty®, 30 µg). The primary endpoint was the rate of 2-fold circulating antibody titre increase 14 days post-vaccination measured by quantitative electrochemiluminescence (ECL) immunoassay, targeting RBD region of Wuhan wild-type SARS-CoV-2. Secondary endpoints included the changes in neutralising capacity against wild-type and 25 variants of concern at 14 days and up to 12 months. Safety was assessed by monitoring of solicited adverse events (AEs) for seven days after on-study vaccination. Unsolicited AEs were collected until the end of follow-up at 12 months, SAEs were pursued for a further 30 days.

    RESULTS: Between 08th of November 2021 and 04th of January 2022, 53 participants ≥75 years received a COVID-19 vaccine as 1st booster. Fifty subjects (BNT162b2 n = 25/mRNA-1273 n = 25) were included in the analyses for immunogenicity at day 14. The primary endpoint of a 2-fold anti-RBD IgG titre increase 14 days after vaccination was reached for all subjects. A 3rd vaccination of full-dose mRNA-1273 provided higher anti-RBD IgG titres (Geometric mean titre) D14 mRNA-127310711 IU/mL (95 %-CI: 8003;14336) vs. BNT162b2: 7090 IU/mL (95 %-CI: 5688;8837). We detected a pattern showing higher neutralising capacity of full-dose mRNA-1273 against wild-type as well as for 23 out of 25 tested variants.

    INTERPRETATION: Third doses of either BNT162b2 or mRNA-1273 provide substantial circulating antibody increase 14 days after vaccination. Full-dose mRNA-1273 provides higher antibody levels with an overall similar safety profile for people ≥75 years.

    FUNDING: This trial was funded by the European Commission (Framework Program HORIZON 2020).

Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links